Ovarian cancer is the fifth-leading cause of cancer-related deaths in the western world. In one of every four women diagnosed, the cancer is resistant to standard first-line chemotherapy. In 2009, through a TFRI Translational Research project, leading ovarian cancer researchers and clinicians from across Canada joined forces to develop a biomarker-driven research program.
An essential part of the program is to link together several collections of cancerous tissues and biobanks through a central platform. This platform is the Canadian Ovarian Experimental Unified Resource (COEUR) and will serve as a comprehensive biological and data resource for the entire biomarker program and the wider research community.
COEUR has been created to promote access, ensure quality, and provide standardization of biological material and data resources for biomarker research in ovarian cancer.
The central research platform is based on a retrospective collection of human epithelial ovarian cancer biological material.
Tissue samples include: high grade serous carcinoma; endometrioid carcinoma; clear cell carcinoma; mucinous carcinoma. The research platform also includes collections of other biological material, such as frozen tissues, blood DNA, serum, plasma, ascites fluids, FFPE samples and TMA, with associated clinical data.